<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134597">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02053779</url>
  </required_header>
  <id_info>
    <org_study_id>27111969</org_study_id>
    <nct_id>NCT02053779</nct_id>
  </id_info>
  <brief_title>Luteal Supplementation With GnRH-agonist After GnRH-agonist Triggering in Combination With Low Dose HCG in IVF</brief_title>
  <official_title>The Impact of a Single Dose of GnRH Agonist (Triptorelin 0,1 mg) at the Time of Implantation on the Reproductive Outcome in IVF Cycles Triggered by a GnRH Agonist Followed by a Small Bolus of HCG the Day of Oocyte Retrieval</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Ibn Rochd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Ibn Rochd</source>
  <oversight_info>
    <authority>Algeria: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose:The aim of this project is to prospectively determine whether a single dose of
      GnRH-agonist  administered at the time of implantation  increases or not the reproductive
      outcome in patients undergoing in vitro fertilization ( IVF)/ intracytoplasmatic sperm
      injection(ICSI) triggered by  a GnRH-agonist  followed by a small bolus of human chorionic
      gonadotropin (hCG 1500 IU) the day of oocyte retrieval.

      Acronyms:

      GnRH: gonadotropin-releasing hormone FSH: follicle stimulating hormone LH: luteinizing
      hormone HCG:human chorionic gonadotropin IVF:In vitro fertilization ICSI:intracytoplasmatic
      sperm injection OHSS:ovarian hyperstimulation syndrome OMEGA: oocyte maturation employing
      GnRH-agonist OPU: ovum pick up NaCl: sodium chloride
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been reported in previous publications that  the ovarian hyperstimulation syndrome
      (OHSS) was eliminated when GnRH agonist was used to trigger ovulation and the delivery rate
      has improved after modified luteal support especially  when a small bolus of hCG is used on
      the day of oocyte retrieval. (OMEGA/HCG 1500 IU).

      However, a risk difference of 7% in delivery rates is still in favor of HCG trigger. Thus,
      further modifications in the luteal phase supplementation are required in order to optimise
      the reproductive outcome after GnRH-agonist triggering.

      Recently, many papers showed, that independently of the GnRH analogue used to prevent the
      premature LH surge, the addition of GnRH-agonist during the luteal phase seems to be
      beneficial in terms of pregnancy. Nevertheless, their use in practice is not yet admitted
      because of controversial results in terms of efficacy and safety particularly on the
      conceptus.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>implantation rate</measure>
    <time_frame>5 weeks after IVF/ICSI</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of gestational sacs per number of embryos transferred</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>chemical pregnancy</measure>
    <time_frame>2 weeks after IVF/ICSI</time_frame>
    <safety_issue>No</safety_issue>
    <description>confirmed by beta-hCG 14 days post embryo transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical pregnancy</measure>
    <time_frame>5 weeks after IVF/ICSI</time_frame>
    <safety_issue>No</safety_issue>
    <description>appearance of yolk sac with foetal heart beat at 7 weeks of gestation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>live birth</measure>
    <time_frame>26 weeks after IVF/ICSI</time_frame>
    <safety_issue>No</safety_issue>
    <description>birth of baby beyond 28 weeks of gestation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ovarian hyperstimulation syndrome OHSS</measure>
    <time_frame>from date of triggering until 2 weeks after pregnancy test</time_frame>
    <safety_issue>No</safety_issue>
    <description>frequency of moderate to severe OHSS</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>GnRH-agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm: Triptorelin 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control Arm: Placebo 1m Nacl 0.9% solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptorelin 0.1mg</intervention_name>
    <description>Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.</description>
    <arm_group_label>GnRH-agonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1 ml Nacl 0.9% solution</intervention_name>
    <description>Placebo 1 ml Nacl 0.9% solution administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female age &lt; 40 years

          -  Baseline FSH and LH &lt; 12 IU/l.

          -  Body Mass Index &gt; 18 and &lt; 35 kg/m2

          -  No uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa
             (hydrosalpinx) abnormalities

          -  Patients with at least one embryo at transfer time

        Exclusion Criteria:

          -  Very high risk of OHSS (&gt; 30 follicles &gt; 12 mm the day of ovulation triggering).

          -  Reduced ovarian reserve

          -  Fertilization failure

          -  Severe endocrinopathy

          -  Azoospermia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelhamid benmachiche, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ibn roch infertility centre, cit√© boussouf, Constantine Algeria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdelhamid benmachiche, Study principal investigator</last_name>
    <phone>00213773112786</phone>
    <email>benmachiche@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>amel boularak, biologist</last_name>
    <phone>00213540261200</phone>
    <email>a.boularak@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ibn Rochd Infertility Centre</name>
      <address>
        <city>Constantine</city>
        <zip>25000</zip>
        <country>Algeria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>abdelhamid benmachiche, doctor</last_name>
      <phone>00213773112786</phone>
      <email>benmachiche@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>amel boularak, biologist</last_name>
      <email>a.boularak@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>abdelhamid benmachiche, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Algeria</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 22, 2014</lastchanged_date>
  <firstreceived_date>January 31, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Ibn Rochd</investigator_affiliation>
    <investigator_full_name>benmachiche abdelhamid</investigator_full_name>
    <investigator_title>Dr benmachiche abdelhamid, private infertility centre, Ibn rochd, constantine, Algeria</investigator_title>
  </responsible_party>
  <keyword>GnRH agonist</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>Luteal phase</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triptorelin</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
